Pfizer stock jumps after avoiding fighting with the field-currently
Boring (PFE) After avoiding the battle with the inside of the radical investor, the stock is defined on Monday.
↑
X
How to buy stocks: 4 factors to find high -quality trade ideas
According to Bloomberg, the Step side did not propose any nomination of the nomination of Pfizer's board of directors before the deadline for January 25. The board of directors will hold an annual meeting in April.
The news reduced the pressure of Pfizer, and the stock increased by 3 % to 26.86. Last year, the Step side received a $ 1 billion of Pfizer. Activist investors claim that Pfizer has not invested in research and development. STARBOARD also believes that Pfizer has formulated decisions of poor capital distribution and has a good prediction and budget.
Nevertheless, Pfizer's stock decreased by 56.5 % from the 60 -peak value above 2021. According to MarketSurge, the stock is now trapped between 50 days and 200 days of moving average.
Pfizer: Bora faced with critics
CEO Albert Bourla is facing a major criticism of the field side.
At the JP Morgan HealthCare conference held in San Francisco this month, Bourla acknowledged that he was not satisfied with Pfel's performance in 2023. The company lost sales expectations during sales in three -quarter sales, because the sales of COVID products reducing the sales of COVID products.
Bla said he proposed five priorities to reverse the situation. The goal involves strengthening pipelines, reversing business performance, maximizing new products and reducing costs.
“I am glad to achieve and surpass all the goals we set in all five priorities in most cases.”
However, since the annual meeting, Pfizer's stock has been unmoved, which is the largest in the industry. According to IBD DIGITAL data, the relative intensity rating of stocks is poor. The score of 1-99 measures the 12-month performance of the stock to all other stocks. The intermediate comprehensive rating of Pfizer's stock is 50, which places its technology and basic performance in the middle of all stocks.
Follow @ibd_agatlin on the Allison Gatlin on X/Twitter.
You may also like:
Akero therapeutics inventory double-extract 89bio in the positive MASH study
The next -generation obesity drugs are better than performance
IBD stocks on the day: see how to find, track and buy the best stock
Use the IBD rankings to purchase and sell alarms in time
Find the best growth stock that uses IBD 50 to watch today